Advances in therapy
-
Advances in therapy · Feb 2008
Case ReportsThe effect of acute normovolaemic haemodilution on blood gas parameters: a case report.
Increased awareness of the risks related to homologous blood transfusions such as immunological reactions, transmission of infections, and immunosuppression, has necessitated exploration of alternative techniques to deal with the needs of intra-operative blood transfusion. Strategies that reduce or remove the risks associated with allogeneic transfusion include pre-operative autologous donation, peri-operative cell-salvage techniques, deliberate hypotension, and pharmacological interventions. Acute normovolaemic haemodilution is another such technique. ⋯ Acute normovolaemic haemodilution with 6% hexaethyl starch is a safe procedure for blood conservation in selected operations. It did not cause any haemodynamic or blood gas parameters to change. It did not have any adverse effect on haemostatic mechanisms that could enhance the risk of bleeding at surgery.
-
Advances in therapy · Jan 2008
Randomized Controlled TrialEfficacy of thoracic epidural analgesia for laparoscopic cholecystectomy.
Postoperative pain is a commonly observed phenomenon after laparoscopic procedures. The use of new low-solubility inhalation anaesthetics leads to faster induction and recovery, but the effect of analgesics on pain when used with them is not sufficiently known. Optimally, analgesic therapy should be started in sufficient time as to be effective at the point of emergence from anaesthesia. We compared the effectiveness of intravenous and epidural analgesia in patients undergoing general anaesthesia with sevoflurane for laparoscopic cholecystectomy in the early postoperative period. ⋯ The epidural technique provided a significant effect on postoperative pain in patients undergoing laparoscopic cholecystectomy.
-
Advances in therapy · Jan 2008
Sevoflurane induction in cyanotic and acyanotic children with congenital heart disease.
The aim of the study was to investigate the induction characteristics of sevoflurane in cyanotic and acyanotic children with congenital heart disease compared with healthy controls in a prospective, controlled, non-blinded study at a university hospital. ⋯ Induction characteristics of sevoflurane in cyanotic and acyanotic children with congenital heart disease and in healthy children are similar. Sevoflurane induction is an effective and well-tolerated technique for cyanotic and acyanotic children with congenital heart disease.
-
Advances in therapy · Nov 2007
Randomized Controlled Trial Comparative StudyEffects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. ⋯ Eyes treated with nepafenac 0.1% or ketorolac 0.4% achieved complete reepithelialization significantly faster than those treated with bromfenac 0.09%. Daily contact lens removal and application of fluorescein may have delayed reepithelialization in the overall population; however, the effect would have been the same in all 3 groups. Pain relief with nepafenac 0.1% was achieved sooner than with ketorolac 0.4% or bromfenac 0.09%.
-
Advances in therapy · Nov 2007
Randomized Controlled TrialProbrain natriuretic peptide for assessment of efficacy in heart failure treatment.
N-terminal probrain natriuretic peptide (NT-proBNP) is elevated in patients with heart failure. Numerous clinical trials have evaluated the efficacy of spironolactone in heart failure; however, no studies have directly examined the effects of spironolactone treatment on NT-proBNP level. This study investigated whether NT-proBNP levels decrease with daily spironolactone treatment. ⋯ The baseline demographic and laboratory parameters were similar for patients in all groups. At the end of 6 mo, spironolactone-treated patients had significantly lower NT-proBNP levels and significantly better ejection fractions than did patients in all New York Heart Association classes who were not treated with spironolactone. Results suggest that spironolactone decreases plasma NT-proBNP concentrations, and that the measurement of plasma NT-proBNP levels may be helpful in assessing therapeutic efficacy in patients who are treated for heart failure.